Microbial manipulation as primary therapy for Crohn's disease Academic Article uri icon

Overview

MeSH Major

  • Anti-Infective Agents
  • Colon
  • Crohn Disease
  • Rifamycins

abstract

  • While antimicrobials are clinically effective in preventing post-operative recurrence, the role for antibiotics in primary therapy for Crohn's disease (CD) remains unclear. The recent multicenter phase 2 trial by Prantera et al received wide attention because it demonstrated an increase in the week 12 remission rate in patients with moderately active CD treated with rifaximin and renewed interest in microbial manipulation as primary therapy for CD. In this commentary, we discuss aspects of durability, immune cell polarization, and safety of microbial manipulation as primary therapy for CD.

publication date

  • March 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3602467

Digital Object Identifier (DOI)

  • 10.3748/wjg.v19.i10.1513

PubMed ID

  • 23539531

Additional Document Info

start page

  • 1513

end page

  • 6

volume

  • 19

number

  • 10